# GI-6301

Source: https://onco.cc/drugs/gi-6301/  
OnCo record `gi-6301` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GI-6301 was a vaccine made from yeast carrying brachyury, the protein that chordomas depend on. Given with radiotherapy in a randomised trial it did not improve tumour responses.

## Summary

GI-6301 was GlobeImmune's Tarmogen vaccine against brachyury, the notochord transcription factor whose expression defines chordoma and which also drives epithelial-to-mesenchymal transition in other cancers. Phase 1 testing at the National Cancer Institute showed brachyury-specific T-cell responses and some disease stabilisation in chordoma. A randomised, placebo-controlled phase 2 trial combined the vaccine with radiotherapy in locally advanced chordoma; it found no difference in objective response between the arms, although the vaccine was safe.

The chordoma page names it with adenoviral brachyury vaccines among the attempts to immunise against brachyury, alongside newer brachyury degraders and CDK7/9 inhibitors that lower its expression.

## Fields

- Kind: Treatment
- Status: negative
- Last checked: 2026-09-17
- Also known as: Yeast-brachyury vaccine
- Tags: subtype-drugs-wave
- Code: GI-6301
- Modality: Heat-killed recombinant yeast vaccine expressing brachyury
- Mechanism: Saccharomyces cerevisiae engineered to express the transcription factor brachyury (TBXT), the driver of chordoma, is injected to raise brachyury-specific T cells; the yeast itself acts as the adjuvant.

## Connected records

- cancers: [Chordoma](https://onco.cc/cancers/chordoma/)
- technologies: [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- companies: [GlobeImmune](https://onco.cc/companies/globeimmune/)

---
JSON: https://onco.cc/api/v1/entities/gi-6301.json